Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ince

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 12, 2014
Influenza A virus nucleoprotein selectively decreases neuraminidase gene-segment packaging while enhancing viral fitness and transmissibilityChristopher B Brooke, William L Ince, Jiajie Wei, et al.
Journal of Virology|July 5, 2023
Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug SusceptibilityBrady T Hickerson, Svetlana N Petrovskaya, Harold Dickensheets, et al.
Journal of Virology|January 4, 2013
Most influenza a virions fail to express at least one essential viral proteinChristopher B Brooke, William L Ince, Jens Wrammert, et al.
Virology Journal|December 1, 2019
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodiesNatalia A Ilyushina, Takashi E Komatsu, William L Ince, et al.
Antiviral Research|April 12, 2019
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conferenceJohn H Beigel, Hannah H Nam, Peter L Adams, et al.
Journal of Virology|June 5, 2009
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouseShailesh K Choudhary, Naser L Rezk, William L Ince, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2011
Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategySuman R Das, Scott E Hensley, Alexandre David, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2022
Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon ExpressionBrady T Hickerson, Simone E Adams, Subrata Barman, et al.
Plos Pathogens|January 19, 2018
Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Plos Pathogens|June 21, 2018
Correction: Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|November 12, 2014
Influenza A virus nucleoprotein selectively decreases neuraminidase gene-segment packaging while enhancing viral fitness and transmissibilityChristopher B Brooke, William L Ince, Jiajie Wei, et al.
Journal of Virology|July 5, 2023
Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug SusceptibilityBrady T Hickerson, Svetlana N Petrovskaya, Harold Dickensheets, et al.
Journal of Virology|January 4, 2013
Most influenza a virions fail to express at least one essential viral proteinChristopher B Brooke, William L Ince, Jens Wrammert, et al.
Virology Journal|December 1, 2019
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodiesNatalia A Ilyushina, Takashi E Komatsu, William L Ince, et al.
Antiviral Research|April 12, 2019
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conferenceJohn H Beigel, Hannah H Nam, Peter L Adams, et al.
Journal of Virology|June 5, 2009
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouseShailesh K Choudhary, Naser L Rezk, William L Ince, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2011
Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategySuman R Das, Scott E Hensley, Alexandre David, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2022
Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon ExpressionBrady T Hickerson, Simone E Adams, Subrata Barman, et al.
Plos Pathogens|January 19, 2018
Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Plos Pathogens|June 21, 2018
Correction: Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Pageof 3